• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

UPDATE: Mylan declines to testify at Senate committee hearing

November 22, 2016 By Sarah Faulkner

Mylan declines to testify at Senate committee hearing

Updated to include the Senate Judiciary Committee’s response.

Mylan (NDSQ:MYL) declined to testify at a U.S. Senate committee regarding its $465 million pending settlement to deal with charges that it underpaid government healthcare programs when it misclassified its EpiPen injector as a generic.

The Canonsburg, Pa.-based company penned a letter to the Senate Judiciary Committee Nov. 18, saying it would not testify because the matter of its settlement with the government is still pending.

“Further, we understand that representatives of those government agencies have confirmed to the committee that they are not able to send a witness to testify or provide further information about this matter while it is pending,” Mylan said in the letter.

Chairman Sen. Chuck Grassley (R-Iowa) said in a statement that Mylan was “ducking responsibility.” Grassley had scheduled the hearing for the end of this month.

“This seems to contradict Mylan’s claim that all potential liability claims have been resolved,” Grassley wrote.

Mylan is working to finalize a settlement with the U.S. government over Medicaid rebates for its EpiPen emergency allergy treatment. The company reported in October that it would pay a $465 million settlement, but the U.S. government has not confirmed the agreement.

The company has been under fire since August, when reports surfaced that it had raised the price of its device by 500% over the past decade. Bresch has since testified before Congress about the company’s pricing strategies, but some politicians are calling on regulatory groups to investigate.

Grassley wrote to the Securities and Exchange Commission yesterday to encourage an investigation, if it isn’t doing so already. “One way or another, I intend to get answers for patients and tax payers,” Grassley wrote in his statement.

The Senate Judiciary Committee said today that it will postpone the hearing while it “considers other avenues to ensure government and company witnesses participate.”

Filed Under: Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Mylan

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS